Z
Zaoqu Liu
Researcher at Zhengzhou University
Publications - 95
Citations - 892
Zaoqu Liu is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 6, co-authored 26 publications receiving 78 citations.
Papers
More filters
Journal ArticleDOI
Editorial: Using multi-omics to develop new strategies to improve prognosis and immunotherapy outcomes in cancers
TL;DR: The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China, Center of Reproductive Medicine, The First affiliated Hospital of Zou et al. as discussed by the authors .
Journal ArticleDOI
Epigenetically Regulated Gene Expression Profiles in Lung Adenocarcinoma Revealed Four Molecular Subtypes with Prognostic and Therapeutic Indications
Yuqing Ren,Zaoqu Liu,Yuyuan Zhang,Siyuan Weng,Hui-Xian Xu,Hongxia Xia,Jing Li,Ping-an Li,Chunya Lu,Libo Wang,Long Liu,Xinwei Han,Guojun Zhang +12 more
Journal ArticleDOI
Immune‐related interaction perturbation networks unravel biological peculiars and clinical significance of glioblastoma
Zaoqu Liu,Yu Ming Xu,Yuhui Wang,Siyuan Weng,Hui-Xian Xu,Yuqing Ren,C-C Guo,Long Liu,Zhenyu Zhang,Xinwei Han +9 more
Posted ContentDOI
Comprehensive machine-learning survival framework develop a consensus model in large scale multi-center cohorts for pancreatic cancer
TL;DR: Wang et al. as discussed by the authors proposed an artificial intelligence-derived prognostic signature (AIDPS) to predict the prognosis and immunotherapy efficacy of pancreatic cancer (PACA) patients.
Journal ArticleDOI
Crosstalk between regulated cell death and immunity in redox dyshomeostasis for pancreatic cancer.
Zhao‐Zong Zhou,Yuyuan Zhang,Jing Li,Siyuan Weng,Jie Liu,Shuang Chen,Jinxiang Lv,Yanping Zhang,Shuaixi Yang,Xinwei Han,Zaoqu Liu,Jianguo Wen +11 more
TL;DR: In this paper , four redox-related subtypes of pancreatic cancer were identified: C1 and C2 displayed malignant phenotypes with dismal clinical outcomes, conspicuous enrichment in cell death pathways, high redox score, low immune activation, and immune-desert tumor immune microenvironment (TIME); C3, an immune-rejection/excluded subtype, with abundant immune cells, high co-stimulatory, co-inhibitory, and MHC molecules, and potential response to immunotherapy; C4, with the best prognosis, low redox pattern, high level of autophagy, low enrichment of most cell death-related pathways, and “immune-hot” TIME.